Bioorganic & Medicinal Chemistry Letters 28 (2018) 2080–2083

Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl

# 2-Methylacrylamide as a bioisoster of thiourea group for 1,3-dibenzylthioureido TRPV1 receptor antagonists

Seol Rin Park [a], Juhyun Kim [a], Sun Young Lee [a], Young-Ho Park [b], Hee-Doo Kim [a,*]

[a] College of Pharmacy, Sookmyung Women's University, Seoul 04310, South Korea
[b] AmorePacific R & D Center, Youngin-Si, Gyeonggi-do 17014, South Korea

ARTICLE INFO

*Article history:*
Received 17 February 2018
Revised 13 April 2018
Accepted 16 April 2018
Available online 17 April 2018

*Keywords:*
2-Methylacrylamide
Bioisoster
TRPV1
1,3-Dibenzylthioureas
Antagonist
$^{45}Ca^{2+}$-Influx assay

ABSTRACT

In order to replace thiourea group with the more drug-like moiety for 1,3-dibenzylthioureas having TRPV1 antagonist activity, we introduced a set of functional groups between the two aromatic rings based on bioisosteric replacement. The synthesized bioisosteres of 1,3-dibenzylthioureas were tested for their antagonist activities on TRPV1 by $^{45}Ca^{2+}$-influx assay using neonatal rat cultured spinal sensory neurons. Among the tested 14 kinds of bioisosters, 2-methylacrylamide group was the best candidate to replace thiourea group. Compound **7c**, 2-methylacrylamide analog of ATC-120, showed as potent as ATC-120 in its antagonist activity. In addition, 2-methylacrylamide analog **7e** having vinyl moiety showed the most potent activity with 0.022 μM of $IC_{50}$ value, indicating that thiourea group of 1,3-dibenzylthioureas could be replaced to 2-methylacrylamide without loss of their potencies.



The transient receptor potential vanilloid-1 (TRPV1) is a ligand-gated nonselective cation channel with high $Ca^{2+}$ permeability,[1] emerging as an attractive target for the treatment of chronic and inflammatory pain.[2] Capsaicin, resiniferatoxin,[3] and SDZ-249482[4] represent the most well-known agonists to date. However, due to their undesirable side effects such as pungency and/or hypothermia responses,[5] recent efforts have been focused on the discovery of novel antagonists.[6] We and co-workers discovered the potent antagonists (MK-056,[7a] SC-0030,[7b,7c] and ATC-120[7d]) by changing phenolic hydroxyl group of SDZ-249482 to the corresponding methanesulfonylamido group (Fig. 1). Over the past few years, we have demonstrated that a series of 1,3-dibenzylthioureas having methanesulfonylamido group were potent TRPV1 antagonists active against multiple activators.[8] In these SAR studies, we have found that thiourea moiety of 1,3-dibenzylthioureas is very important pharmacophore for their high potencies. However, in view of drug-like properties, there is a need to develop the more drug-like moiety than is thiourea. Thus, we decide to investigate the new pharmacophoric alternatives to replace thiourea group of the 1,3-dibenzylthiourea series.

A number of functional groups including urea, amide, acrylamide and glycolamide were chosen as bioisosteres of thiourea. ATC-120 was also chosen as reference compounds in order to clarify the effect of bioisosteric replacement. The target compounds were synthesized *via* the route outlined in Scheme 1–5. 4-Methanesulfonamido-α-methylbenzylamines **5a–c** were coupled with 4-*tert*-butylbenzenes **6a–e** having the requisite functional groups. (*S*)-4-Methanesulfonamido-α-methylbenzylamine (**5a**) and (*S*)-3-Fluoro-4-methanesulfonamido-α-methylbenzylamine (**5b**) were prepared according to the previously reported methods.[7d,9] (*S*)-3-Vinyl-4-methanesulfonamido-α-methylbenzylamine (**5c**) was prepared *via* the route outlined in Scheme 1. Treatment of **1** with iodine monochloride produced **2** regioselectively in 47% yield. The iodide **2** was then converted the vinyl compound **3** using by Stille's coupling, followed by methanesulfonylation and deprotection to give the (*S*)-3-vinyl-4-methanesulfonamido-α-methylbenzylamine (**5c**).

At first, we made urea analog **7a** as a thiourea bioisoster of ATC-120, as shown in Scheme 2. (*S*)-4-Methanesulfonamido-α-methylbenzylamine **5a** was treated with 4-*tert*-butylbenzylisocyanate **6a** under basic condition followed by deprotection to give the urea analog **7a** in 17% yield.

Next, we focused on the design and synthesis of amide analogs due to their drug-like properties. Amides, acrylamides, thioamides, and thioacrylamides were designed and prepared *via* the route outlined in Scheme 3. (*S*)-4-Methanesulfonamido-α-methylbenzylamines (**5a–c**) were treated with (*E*)-3-[4-(*tert*-butyl)phenyl] acrylic acid (**6b**) or (*E*)-3-[4-(*tert*-butyl)phenyl]-2-methylacrylic acid (**6c**) with an aid of coupling agent DEPC under basic condition

* Corresponding author.
*E-mail address:* hdkim@sookmyung.ac.kr (H.-D. Kim).

https://doi.org/10.1016/j.bmcl.2018.04.044
0960-894X/




**Fig. 1.** Structure of capsaicin and 1,3-dibenzylthioureas.



**Scheme 1.** Synthesis of chiral amine **5c**: (a) ICl, $CH_2Cl_2$, 47%; (b) $Bu_3SnCH=CH_2$, LiCl, $Pd(PPh_3)_4$, DMF, reflux, 72%; (c) $(CH_3SO_2)_2O$, pyridine, $CH_2Cl_2$, 47%; (d) $CF_3CO_2H$, $CH_2Cl_2$, 100%.



**Scheme 2.** Synthesis of urea **7a**: (a) TEA, $CH_2Cl_2$, then $CF_3CO_2H$, 17%.

in DMF to produce the corresponding (methyl)acrylamides **7b**–**e** in 55–94% yields. Double bond reduction of (methyl)acrylamides **7b**–**c** by hydrogenolysis gave the (methyl)amides **7f**–**g** in good yields.



**Scheme 5.** Synthesis of propiolamide: (a) DEPC, TEA, DMF, 61%.

Treatment of **7b** or **7f** with Lawesson's reagent gave the corresponding thio(acryl)amide **7h** or **7i** respectively.

We also designed the glycolamides **7j**,**k** and its analogs **7l** and **7m** as a bioisoster of thiourea ATC-120. Synthese of **7j**–**m** are outlined in Scheme 4. (*S*)-4-Methanesulfonamido-α-methylbenzylamines (**5a**–**b**) were treated with 2-[4-(*tert*-butyl)phenoxy]acetic acid (**6d**) with an aid of coupling agent DEPC under basic condition in DMF to produce the corresponding glycolamides **7j**,**k**. Treatment of **7j** with Lawesson's reagent gave the corresponding thioglycolamide **7l** in 88% yield. By reacting with cyanamide and $HgCl_2$, thioglycolamide **7l** could be converted to the corresponding *N*-cyanoacetimidamide **7m** in 98% yield.

Finally, we designed propiolamide as a bioisoster of thiourea of ATC-120. (*S*)-4-Methanesulfonamido-α-methylbenzylamine (**5a**) was treated with 2-[4-(*tert*-butyl)phenyl] propiolic acid (**6e**) with an aid of coupling agent DEPC under basic condition in DMF to produce the corresponding propiolamide **7n**, as shown in Scheme 5.

The prepared bioisosters for ATC-120 were tested for their antagonist activities on TRPV1 by $^{45}Ca^{2+}$-influx assay using neonatal rat cultured spinal sensory neurons.[10] The results are summarized in Table 1. ATC-120 was used as reference compound. As is anticipated, urea analog **7a** showed 13-fold decrease in antagonist activity compared to thiourea analog ATC-120. Amide analogs **7f**, methyl-branched amide **7g**, and thioamide **7h** were less potent than thiourea analog ATC-120, but more active than urea analog **7a**. When an oxygen atom is introduced to β-position in place of




**Scheme 3.** Synthesis of amides and thioamides: (a) DEPC, TEA, DMF, 55–94%; (b) $H_2$, Pd/C, quant.; (c) Lawesson's reagent, toluene, reflux, 87%; (d) Lawesson's reagent, toluene, reflux, 87%.




**Scheme 4.** Synthesis of glycolamides and its analogs: (a) DEPC, TEA, DMF, 77–88%; (b) Lawesson's reagent, toluene, reflux, 88%; (c) $HgCl_2$, $H_2NCN$, TEA, DMF, 98%.